Toll Free: 1-888-928-9744

African Trypanosomiasis - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

African Trypanosomiasis - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides an overview of the African Trypanosomiasis (Infectious Disease) pipeline landscape.

African trypanosomiasis (also known as African sleeping sickness) is a parasitic infection caused by a species of parasite, Trypanosoma brucei, which is transmitted to humans through the bite of the tsetse fly. Symptoms include anxiety, drowsiness during the day, fever, headache, insomnia at night, mood changes, sleepiness (may be uncontrollable), sweating, swollen lymph nodes all over the body, swollen, red, painful nodule at site of fly bite and weakness. Treatment includes anti-protozoal agents. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide African Trypanosomiasis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for African Trypanosomiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The African Trypanosomiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 3 molecules, respectively.

African Trypanosomiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of African Trypanosomiasis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for African Trypanosomiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in African Trypanosomiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates African Trypanosomiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for African Trypanosomiasis (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for African Trypanosomiasis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding African Trypanosomiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage African Trypanosomiasis - Overview African Trypanosomiasis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes African Trypanosomiasis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type African Trypanosomiasis - Companies Involved in Therapeutics Development Incuron LLC Novartis AG Sanofi Scynexis Inc African Trypanosomiasis - Drug Profiles AN-5568 - Drug Profile Product Description Mechanism Of Action R&D Progress CBL-0137 - Drug Profile Product Description Mechanism Of Action R&D Progress DDD-100097 - Drug Profile Product Description Mechanism Of Action R&D Progress fexinidazole - Drug Profile Product Description Mechanism Of Action R&D Progress GNF-6702 - Drug Profile Product Description Mechanism Of Action R&D Progress melarsoprol hydroxypropylbetadex - Drug Profile Product Description Mechanism Of Action R&D Progress MS-08 - Drug Profile Product Description Mechanism Of Action R&D Progress Peptides for Sleeping Sickness - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Infectious Diseases - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Sleeping Sickness - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Leucyl-tRNA Synthetase (LeuRS) for Human African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis - Drug Profile Product Description Mechanism Of Action R&D Progress African Trypanosomiasis - Dormant Projects African Trypanosomiasis - Discontinued Products African Trypanosomiasis - Product Development Milestones Featured News & Press Releases Aug 30, 2016: UGA researchers discover a drug for a tropical disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for African Trypanosomiasis, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 African Trypanosomiasis - Pipeline by Incuron LLC, H1 2017 African Trypanosomiasis - Pipeline by Novartis AG, H1 2017 African Trypanosomiasis - Pipeline by Sanofi, H1 2017 African Trypanosomiasis - Pipeline by Scynexis Inc, H1 2017 African Trypanosomiasis - Dormant Projects, H1 2017 African Trypanosomiasis - Discontinued Products, H1 2017



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify